Tumour-infiltrating neutrophils counteract anti-VEGF therapy in metastatic colorectal cancer
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Immune infiltration is implicated in the development of acquired resistance to anti-angiogenic cancer therapy. We therefore investigated the correlation between neutrophil infiltration in metastasis of colorectal cancer (CRC) patients and survival after treatment with bevacizumab. Our study identifies CD177+ tumour neutrophil infiltration as an adverse prognostic factor for bevacizumab treatment. We further demonstrate that a novel anti-VEGF/anti-Ang2 compound (BI-880) can overcome resistance to VEGF inhibition in experimental tumour models. METHODS: A total of 85 metastatic CRC patients were stratified into cohorts that had either received chemotherapy alone (n = 39) or combined with bevacizumab (n = 46). Tumour CD177+ neutrophil infiltration was correlated to clinical outcome. The impact of neutrophil infiltration on anti-VEGF or anti-VEGF/anti-Ang2 therapy was studied in both xenograft and syngeneic tumour models by immunohistochemistry. RESULTS: The survival of bevacizumab-treated CRC patients in the presence of CD177+ infiltrates was significantly reduced compared to patients harbouring CD177- metastases. BI-880 treatment reduced the development of hypoxia associated with bevacizumab treatment and improved vascular normalisation in xenografts. Furthermore, neutrophil depletion or BI-880 treatment restored treatment sensitivity in a syngeneic tumour model of anti-VEGF resistance. CONCLUSIONS: Our findings implicate CD177 as a biomarker for bevacizumab and suggest VEGF/Ang2 inhibition as a strategy to overcome neutrophil associated resistance to anti-angiogenic treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neutrophils in cancer: Neutral no more
Coffelt, S. B., Wellenstein, M. D., & de Visser, K. E. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2016.52 · Cited by 1,830
IL-17-producing γδ T cells and neutrophils conspire to promote breast cancer metastasis
Coffelt, S. B., Kersten, K., Doornebal, C. W., Weiden, J., Vrijland, K., Hau, C.-S., Verstegen, N. J. M., Ciampricotti, M., Hawinkels, L. J. A. C., Jonkers, J., et al. (2015) · Nature · doi:10.1038/nature14282 · Cited by 1,703
Macrophage Regulation of Tumor Responses to Anticancer Therapies
De Palma, M., & Lewis, C. E. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.02.013 · Cited by 1,079
Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells
Shojaei, F., Wu, X., Malik, A. K., Zhong, C., Baldwin, M. E., Schanz, S., Fuh, G., Gerber, H.-P., & Ferrara, N. (2007) · Nature Biotechnology · doi:10.1038/nbt1323 · Cited by 849 · cited 1×
“Strikingly, anti-VEGF treatment appeared to trigger the recruitment of myeloid cells into the tumour that conferred resistance to anti-angiogenic treatment especially in colorectal cancer.(10) This treatment resistance could be overcome, however, when immune cell recruitment was disrupted.”
BackgroundMazzieri, R., Pucci, F., Moi, D., Zonari, E., Ranghetti, A., Berti, A., Politi, L. S., Gentner, B., Brown, J. L., Naldini, L., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.02.005 · Cited by 639
Neutrophils in the tumor microenvironment
Powell, D. R., & Huttenlocher, A. (2016) · Trends in Immunology · doi:10.1016/j.it.2015.11.008 · Cited by 578
An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy
Chung, A. S., Wu, X., Zhuang, G., Ngu, H., Kasman, I., Zhang, J., Vernes, J.-M., Jiang, Z., Meng, Y. G., Peale, F. V., et al. (2013) · Nature Medicine · doi:10.1038/nm.3291 · Cited by 445
Peterson, T. E., Kirkpatrick, N. D., Huang, Y., Farrar, C. T., Marijt, K. A., Kloepper, J., Datta, M., Amoozgar, Z., Seano, G., Jung, K., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1525349113 · Cited by 317
Ly6Clo monocytes drive immunosuppression and confer resistance to anti-VEGFR2 cancer therapy
Jung, K., Heishi, T., Khan, O. F., Kowalski, P. S., Incio, J., Rahbari, N. N., Chung, E., Clark, J. W., Willett, C. G., Luster, A. D., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci93182 · Cited by 164
Reardon, D. A., Lassman, A. B., Schiff, D., Yunus, S. A., Gerstner, E. R., Cloughesy, T. F., Lee, E. Q., Gaffey, S. C., Barrs, J., Bruno, J., et al. (2018) · Cancer · doi:10.1002/cncr.31172 · Cited by 50 · cited 1×
“In contrast, a phase I trial for AMG 386 (trebananib)—a dual inhibitor of both Ang1 and Ang2—reported negative results in patients when combined with bev or in patients who had received bev treatment prior to the study.(29) This may not be entirely surprising given that Ang1 and Ang2 have largely antagonistic activiti…”
Background
Cited by
Neutrophil diversity and plasticity in tumour progression and therapy
Jaillon, S., Ponzetta, A., Di Mitri, D., Santoni, A., Bonecchi, R., & Mantovani, A. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-020-0281-y · Cited by 1,285
Deterministic reprogramming of neutrophils within tumors
Ng, M. S. F., Kwok, I., Tan, L., Shi, C., Cerezo-Wallis, D., Tan, Y., Leong, K., Calvo, G. F., Yang, K., Zhang, Y., et al. (2024) · Science · doi:10.1126/science.adf6493 · Cited by 389
Tumor-Associated Neutrophils in Cancer: Going Pro
Wu, L., Saxena, S., Awaji, M., & Singh, R. K. (2019) · Cancers · doi:10.3390/cancers11040564 · Cited by 337
IL8, Neutrophils, and NETs in a Collusion against Cancer Immunity and Immunotherapy
Teijeira, A., Garasa, S., Ochoa, M. C., Villalba, M., Olivera, I., Cirella, A., Eguren-Santamaria, I., Berraondo, P., Schalper, K. A., de Andrea, C. E., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1319 · Cited by 268
Neutrophils as potential therapeutic targets in hepatocellular carcinoma
Geh, D., Leslie, J., Rumney, R., Reeves, H. L., Bird, T. G., & Mann, D. A. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00568-5 · Cited by 218
Metadata
- Authors
- Schiffmann, L. M., Fritsch, M., Gebauer, F., Günther, S. D., Stair, N. R., Seeger, J. M., Thangarajah, F., Dieplinger, G., Bludau, M., Alakus, H., Göbel, H., Quaas, A., Zander, T., Hilberg, F., Bruns, C. J., Kashkar, H., & Coutelle, O.
- Venue
- British Journal of Cancer
- Published
- 2018-10-31
- Volume
- 120
- Issue
- 1
- Pages
- 69-78
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2899252841
- Cited by
- 79
- References
- 10
- FWCI
- 2.12
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tumour-infiltrating neutrophils counteract anti-VEGF therapy in metastatic colorectal cancer. https://app.cochat.ai/papers/10.1038/s41416-018-0198-3
- The paper
- Schiffmann, L. M., Fritsch, M., Gebauer, F., Günther, S. D., Stair, N. R., Seeger, J. M., Thangarajah, F., Dieplinger, G., Bludau, M., Alakus, H., Göbel, H., Quaas, A., Zander, T., Hilberg, F., Bruns, C. J., Kashkar, H., & Coutelle, O. (2019). Tumour-infiltrating neutrophils counteract anti-VEGF therapy in metastatic colorectal cancer. British Journal of Cancer. https://doi.org/10.1038/s41416-018-0198-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.